Boston Scientific Accounts Receivable decreased by 1.2% to $2.93B in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 14.4%, from $2.56B to $2.93B. Over 5 years (FY 2020 to FY 2025), Accounts Receivable shows an upward trend with a 13.8% CAGR.
An increase relative to sales may signal slowing collections or credit risk, while a decrease suggests efficient cash conversion.
The total amount of credit extended to customers and channel partners for products sold or services rendered, minus an a...
Typically scales with revenue growth; however, companies with strong direct-to-consumer channels may have lower receivables relative to those relying on third-party distributors.
accounts_receivable_net| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $1.78B | $1.78B | $1.78B | $1.98B | $2.03B | $1.99B | $1.97B | $2.19B | $2.26B | $2.23B | $2.23B | $2.41B | $2.51B | $2.61B | $2.56B | $2.81B | $2.93B | $2.96B | $2.93B |
| QoQ Change | — | -0.2% | +0.0% | +11.3% | +2.8% | -2.4% | -0.8% | +11.4% | +3.1% | -1.5% | +0.1% | +8.3% | +3.8% | +4.2% | -2.0% | +9.7% | +4.3% | +1.2% | -1.2% |
| YoY Change | — | — | — | — | +14.2% | +11.7% | +10.8% | +10.9% | +11.2% | +12.1% | +13.1% | +10.0% | +10.8% | +17.3% | +14.8% | +16.3% | +16.8% | +13.4% | +14.4% |